Resultats de la cerca - Cui, Chengxu

Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐cente... per Jiang, Zhichao, Sun, Yongkun, Zhang, Wen, Cui, Chengxu, Yang, Lin, Zhou, Aiping

Obtenir text complet Obtenir text complet Obtenir text complet

XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer per CUI, CHENGXU, SHU, CHANG, YANG, YI, LIU, JUNBAO, SHI, SHUPING, SHAO, ZHUJUN, WANG, NAN, YANG, TING, HU, SONGNIAN

Obtenir text complet Obtenir text complet Obtenir text complet

Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial per Zhang, Wen, Du, Chunxia, Sun, Yongkun, Yang, Lin, Cui, Chengxu, Jiang, Zhichao, Wang, Chengfeng, Wang, Jinwang, Zhou, Aiping

Obtenir text complet Obtenir text complet Obtenir text complet

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer per Song, Yan, Qu, Tao, Zhang, Honggang, Sun, Yongkun, Cui, Chengxu, Chi, Yihebali, Zhang, Wen, Wang, Xingyuan, Yang, Lin

Obtenir text complet Obtenir text complet Obtenir text complet

UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens per Cui, Chengxu, Shu, Chang, Cao, Dandan, Yang, Yi, Liu, Junbao, Shi, Shuping, Shao, Zhujun, Wang, Nan, Yang, Ting, Liang, Hao, Zou, Shanshan, Hu, Songnian

Obtenir text complet Obtenir text complet Obtenir text complet

Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy per Shang, Bingqing, Cao, Chuanzhen, Jiang, Weixing, Shi, Hongzhe, Bi, Xingang, Cui, Chengxu, Shou, Jianzhong, Zheng, Shan, Zhang, Jin, Zhou, Aiping, Li, Changling, Ma, Jianhui

Obtenir text complet Obtenir text complet Obtenir text complet

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial per Qin, Shukui, Bi, Feng, Gu, Shanzhi, Bai, Yuxian, Chen, Zhendong, Wang, Zishu, Ying, Jieer, Lu, Yinying, Meng, Zhiqiang, Pan, Hongming, Yang, Ping, Zhang, Helong, Chen, Xi, Xu, Aibing, Cui, Chengxu, Zhu, Bo, Wu, Jian, Xin, Xiaoli, Wang, Jufeng, Shan, Jinlu, Chen, Junhui, Zheng, Zhendong, Xu, Li, Wen, Xiaoyu, You, Zhenyu, Ren, Zhenggang, Liu, Xiufeng, Qiu, Meng, Wu, Liqing, Chen, Feng

Obtenir text complet Obtenir text complet Obtenir text complet

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label pha... per Xu, Jianming, Li, Yi, Fan, Qingxia, Shu, Yongqian, Yang, Lei, Cui, Tongjian, Gu, Kangsheng, Tao, Min, Wang, Xiuwen, Cui, Chengxu, Xu, Nong, Xiao, Juxiang, Gao, Quanli, Liu, Yunpeng, Zhang, Tao, Bai, Yuxian, Li, Wei, Zhang, Yiping, Dai, Guanghai, Ma, Dong, Zhang, Jingdong, Bai, Chunmei, Huang, Yunchao, Liao, Wangjun, Wu, Lin, Chen, Xi, Yang, Yan, Wang, Junye, Ji, Shoujian, Zhou, Hui, Wang, Yan, Ma, Zhuo, Wang, Yanqi, Peng, Bo, Sun, Jiya, Mancao, Christoph

Obtenir text complet Obtenir text complet Obtenir text complet